CEMI Chembio Diagnostics

CEMI, a maker of a rapid test for HIV, syphilis, and canine leishmaniasis, has had a large 20k bid at $4.54 to $4.56 range. The 50 day average volume is just under 17,000 shares so this one bid represents a whole days worth of volume. Perhaps this $4.50-$4.55 range is a solid spot of support? The company itself is profitable and growing rapidly. Future profits could swell significantly if widespread use of the rapid HIV test becomes common or mandatory due to regulations.